Company
Profile

Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Our lead program, JADE-001, targets the anti-APRIL (A PRoliferation-Inducing Ligand) pathway for the treatment of IgA Nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE-001 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.

A first-in-human clinical trial is expected to begin in the second half of 2025, with initial data anticipated in the first half of 2026. In addition to JADE-001, our pipeline includes JADE-002 and JADE-003, two undisclosed optimized antibody programs.